Anantha-Narayanan M, Anugula D, Das G. Patent foramen ovale closure reduces recurrent stroke risk in cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials. World J Cardiol 2018; 10(6): 41-48 [PMID: 29983901 DOI: 10.4330/wjc.v10.i6.41]
Corresponding Author of This Article
Mahesh Anantha-Narayanan, MD, Academic Fellow, Doctor, Division of Cardiovascular Diseases, Department of Medicine, University of Minnesota, Mayo Mail Code 508, 420 Delaware St SE, Minneapolis, MN 55455, United States. manantha@umn.edu
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Jun 26, 2018; 10(6): 41-48 Published online Jun 26, 2018. doi: 10.4330/wjc.v10.i6.41
Patent foramen ovale closure reduces recurrent stroke risk in cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials
Mahesh Anantha-Narayanan, Dixitha Anugula, Gladwin Das
Mahesh Anantha-Narayanan, Gladwin Das, Division of Cardiovascular Disease, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, United States
Dixitha Anugula, Division of Cardiology, CHI Health Creighton University Medical Center, Omaha, NE 68124, United States
Author contributions: All authors contributed to the manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
PRISMA 2009 Checklist statement: The manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Mahesh Anantha-Narayanan, MD, Academic Fellow, Doctor, Division of Cardiovascular Diseases, Department of Medicine, University of Minnesota, Mayo Mail Code 508, 420 Delaware St SE, Minneapolis, MN 55455, United States. manantha@umn.edu
Telephone: +1-612-6262451 Fax: +1-612-6264411
Received: January 31, 2018 Peer-review started: January 31, 2018 First decision: February 27, 2018 Revised: March 1, 2018 Accepted: March 18, 2018 Article in press: March 18, 2018 Published online: June 26, 2018 Processing time: 146 Days and 7 Hours
Core Tip
Core tip: The American Association of Neurology guidelines focused update recommended against routine patent foramen ovale (PFO) closure in patients with cryptogenic stroke; but two recent randomized trials showed a significant reduction in recurrent stroke events in patients who had a PFO closure device when compared to patients on medical therapy alone. We therefore, performed a systematic review & meta-analysis of five available randomized controlled clinical trials that addressed the efficacy of PFO closure in patients with cryptogenic stroke. Our analysis shows PFO closure device in appropriately selected patient population is associated with reduction in recurrent stroke events but at the cost of increase in incidence of atrial fibrillation.
